The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients
Abstract Background One of the crucial functions of the immune system is to prevent tumorigenesis, yet cancer occurs when malignant cells manage to evade immune surveillance via multiple strategies. Accordingly, this study aimed at assessing the potential significance of the novel immune checkpoint...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2021-10-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-021-00198-1 |
| _version_ | 1819143418741260288 |
|---|---|
| author | Sara M. Radwan Nooran S. Elleboudy Nermeen A. Nabih Amal El-kholy Amany M. Kamal |
| author_facet | Sara M. Radwan Nooran S. Elleboudy Nermeen A. Nabih Amal El-kholy Amany M. Kamal |
| author_sort | Sara M. Radwan |
| collection | DOAJ |
| description | Abstract Background One of the crucial functions of the immune system is to prevent tumorigenesis, yet cancer occurs when malignant cells manage to evade immune surveillance via multiple strategies. Accordingly, this study aimed at assessing the potential significance of the novel immune checkpoint B and T lymphocyte attenuator (BTLA) as a prognostic marker in acute myeloid leukemia (AML), in addition to how it relates to response to treatment and patients’ survival. Thus, mRNA expression of BTLA was investigated on peripheral blood in 60 AML patients and 15 healthy controls. Results BTLA expression was found to be significantly elevated (p = 0.024) in the tested AML cases in comparison with healthy controls. Moreover, BTLA was over-expressed in the CD13, CD33, and HLA-DR positive cases as compared to their negative counterparts (p = 0.003; p < 0.001, and p = 0.001, respectively), and cases showing BTLA over-expression had significantly poorer overall survival times (p = 0.001) as confirmed by Kaplan–Meier survival analysis. Conclusion These observations suggest that BTLA over-expression may be associated with reduced immunity against tumors and could be recommended as a promising biomarker for unfavorable prognosis in AML. |
| first_indexed | 2024-12-22T12:25:56Z |
| format | Article |
| id | doaj.art-92f4c2a9ef814819b62d9260dfb5a756 |
| institution | Directory Open Access Journal |
| issn | 2090-2441 |
| language | English |
| last_indexed | 2024-12-22T12:25:56Z |
| publishDate | 2021-10-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Journal of Medical Human Genetics |
| spelling | doaj.art-92f4c2a9ef814819b62d9260dfb5a7562022-12-21T18:25:49ZengSpringerOpenEgyptian Journal of Medical Human Genetics2090-24412021-10-012211810.1186/s43042-021-00198-1The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patientsSara M. Radwan0Nooran S. Elleboudy1Nermeen A. Nabih2Amal El-kholy3Amany M. Kamal4Biochemistry Department, Faculty of Pharmacy, Ain Shams UniversityMicrobiology and Immunology Department, Faculty of Pharmacy, Ain Shams UniversityInternal Medicine Department, Clinical Hematology Division, Faculty of Medicine, Ain Shams UniversityClinical Pharmacy Department, Faculty of Pharmacy, Ain Shams UniversityBiochemistry Department, Faculty of Pharmacy, Ain Shams UniversityAbstract Background One of the crucial functions of the immune system is to prevent tumorigenesis, yet cancer occurs when malignant cells manage to evade immune surveillance via multiple strategies. Accordingly, this study aimed at assessing the potential significance of the novel immune checkpoint B and T lymphocyte attenuator (BTLA) as a prognostic marker in acute myeloid leukemia (AML), in addition to how it relates to response to treatment and patients’ survival. Thus, mRNA expression of BTLA was investigated on peripheral blood in 60 AML patients and 15 healthy controls. Results BTLA expression was found to be significantly elevated (p = 0.024) in the tested AML cases in comparison with healthy controls. Moreover, BTLA was over-expressed in the CD13, CD33, and HLA-DR positive cases as compared to their negative counterparts (p = 0.003; p < 0.001, and p = 0.001, respectively), and cases showing BTLA over-expression had significantly poorer overall survival times (p = 0.001) as confirmed by Kaplan–Meier survival analysis. Conclusion These observations suggest that BTLA over-expression may be associated with reduced immunity against tumors and could be recommended as a promising biomarker for unfavorable prognosis in AML.https://doi.org/10.1186/s43042-021-00198-1Immune checkpointsT-cellsB and T lymphocyte attenuator (BTLA)Acute myeloid leukemia |
| spellingShingle | Sara M. Radwan Nooran S. Elleboudy Nermeen A. Nabih Amal El-kholy Amany M. Kamal The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients Egyptian Journal of Medical Human Genetics Immune checkpoints T-cells B and T lymphocyte attenuator (BTLA) Acute myeloid leukemia |
| title | The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients |
| title_full | The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients |
| title_fullStr | The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients |
| title_full_unstemmed | The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients |
| title_short | The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients |
| title_sort | prospective prognostic value of the immune checkpoint btla expression in adult acute myeloid leukemia patients |
| topic | Immune checkpoints T-cells B and T lymphocyte attenuator (BTLA) Acute myeloid leukemia |
| url | https://doi.org/10.1186/s43042-021-00198-1 |
| work_keys_str_mv | AT saramradwan theprospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT nooranselleboudy theprospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT nermeenanabih theprospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT amalelkholy theprospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT amanymkamal theprospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT saramradwan prospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT nooranselleboudy prospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT nermeenanabih prospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT amalelkholy prospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients AT amanymkamal prospectiveprognosticvalueoftheimmunecheckpointbtlaexpressioninadultacutemyeloidleukemiapatients |